NCT04382456已完成不适用
An Exploratory Pilot Study to Evaluate the Impact of Alpinia Acacia Gum on Microbiome and Bowel Function in Subjects With Chronic Constipation
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 2
- 主要终点
- Gut microbiota
研究概览
简要总结
Proof of concept study to investigate the impact of a food supplement consisting of Acacia gum on changes of gut microbiota and production of short chain fatty acids. Additionally, safety, tolerability and parameters of bowel function (stool frequency, stool consistency and gastrointestinal symptoms) will be assessed during the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 25 Years 至 60 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Healthy subjects without clinical diagnosed diseases with relevant effect on the gastrointestinal system or on visceral motility
- •Constipation defined as an average of 2 - 3 stools per week (which needs to be confirmed during a prospective run-in phase)
- •At least one of the following criteria:
- •straining during more than 25% of defecations
- •lumpy or hard stools (Bristol Stool Form Scale 1 or 2) present more than 25% of defecations
- •sensation of incomplete evacuation in more than 25% of defecations
- •sensation of anorectal obstruction/ blockage in more than 25% of defecations
- •manual manoeuvre to facilitate more than 25% of defecations (such as digital evacuation or support from pelvic floor)
- •Criteria of constipation for at least the previous 3 months
- •BMI 18.5 - 30 kg/m2
- •Stable body weight (+/- 5%) in the last 3 months (self-reported)
- •Willing to maintain normal background dietary habits & physical activity levels throughout the study period
- •Written consent to participate in the study
排除标准
- •Relevant history or presence of any severe medical disorder, potentially interfering with this study in the investigator's judgement (e.g. mal absorption, food intolerance or allergy, chronic gastro-intestinal diseases (e.g. Morbus Crohn, Colitis Ulcerosa), chronic kidney or liver disease, severe depression, immunological disorders, severe cardiovascular disease, diabetes, acute malignant disease within last 3 years except basal cell carcinoma of the skin)
- •Prior abdominal surgery which may present a risk for the subject or confound the study results (according to the investigator's opinion)
- •Currently (or in the last 3 months) suffering from significant stress, anxiety or depression which, in the subjects opinion, interferes with normal daily life (e.g. has the subject missed days of work due to these conditions) and/or which could be responsible for gastrointestinal problems
- •Exclusively vegan or vegetarian diet (high fiber content)
- •Regular laxative use at least once per week
- •Use of hypolipidaemic drugs (e.g. statins, fibrates, resins, ezetimibe, niacin)
- •Subject under prescription for medication or taking dietary supplements possibly interfering with this study (such as anti-spasmodic, laxatives and anti-diarrheic drugs or other digestive auxiliaries, use of PPIs, bismuth salts and/or H2-antagonists, fibers etc.) within 2 weeks prior to study start or during the study; Stable medication (more than 3 months) for hypertension or thyroid gland is allowed.
- •Use of pre- and probiotic supplements
- •Subjects consuming
- •food or drinks claimed as 'probiotic', or 'prebiotic more than once weekly
- •food or drinks claimed as 'rich in fiber' (including specific milk products) more than 3 times per week
- •more than 3 portions of fruits and vegetables (sum) per day
- •Intake of antibiotics in the last 4 weeks
- •Pregnancy or breastfeeding (also exclude recent pregnancy in the last 3 months). A pregnancy test will be conducted during screening and visits 1 -
- •Currently or recently (within 3 months of study entry) taking any medication, which in the opinion of the investigator, could interfere with the outcome of the study, e.g. opioids, anti-psychotics
结局指标
主要结局
Gut microbiota
时间窗: day 1, day 43 and day 71
Composition and diversity (Shannon index), Lactobacillogenic and bifidogenic level, Distribution of bacterial taxa at the phylum, family and genus level, Shifts of specific bacterial taxa
次要结局
- Stool consitency(day -14 (run-in phase) until day 70 (end of follow up))
- Gastrointestinal symptoms(day -14 (run-in phase) until day 70 (end of follow up))
- Blood biomarker(day 1, day 43 and day 71)
- Stool frequency(day -14 (run-in phase) until day 70 (end of follow up))
- Stool biomarker(day 1, day 43 and day 71)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
不适用
The Effect of the Association EGCG, Folic Acid and Vitamin B12 in Preventing the Persistence of HPV Infection.HPV InfectionNCT06285357Lo.Li.Pharma s.r.l100
已完成
不适用
Effects of Phytonutrients Upon Muscle Perfusion in Response to FeedingBiological AgingNCT03213340Abbott Nutrition39
已完成
不适用
Canola Oil, Fibre and DHA Enhanced Clinical TrialMetabolic SyndromeNCT02091583University of Manitoba30
撤回
不适用
The Effects of a Food Product Containing Mushroom Extracts (AndoSanTM) in Subjects With Colorectal Cancer-related FatigueCancer-related FatigueNCT06599710Mycotech Pharma AS30
已完成
不适用
A Clinical Study to Assess the Effect of a Supplement on Digestive Health, Overall Well-being, and Participant Experience.Digestive System DiseaseNCT06283732Amway Corp70